Gain Therapeutics Inc. (GANX) NASDAQ
$2.67 0.05 (1.72%)
Market Cap: $47.30M
As of 05/16/24 03:59 PM EDT. Market closed.
Gain Therapeutics Inc. (GANX)
NASDAQ
$2.67
0.05 (1.72%)
Market Cap: $47.30M
As of 05/16/24 03:59 PM EDT. Market closed.
Add to Portfolio
gain therapeutics is a preclinical stage biotech company specializing in the discovery of new drugs for orphan diseases. the company targets inborn errors of metabolism; a group of rare diseases of genetic origin with a high unmet medical need. gain therapeutics is also working on a new class of compounds: non-competitive pharmacological chaperones, identified through its innovative proprietary ... read more
COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Full Time Employees
27
Address
.
PRICE CHART FOR GAIN THERAPEUTICS INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$2.74
Previous Close
$2.62
Days Range
$2.40 - $2.65
52 week range
$2 - $5.33
Volume
128,614
Avg. Volume (30 days)
117,122
Market Cap
$47.30M
Dividend Yield
-
P/E
(2.12)
Shares Outstanding
18,051,979
Open
$2.74
Previous Close
$2.62
Days Range
$2.40 - $2.65
52 week range
$2 - $5.33
Volume
128,614
Avg. Volume (30 days)
117,122
Market Cap
$47.30M
Dividend Yield
-
P/E
(2.12)
Shares Outstanding
18,051,979
FINANCIAL STATEMENTS FOR GAIN THERAPEUTICS INC
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR GAIN THERAPEUTICS INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Riley Jeffrey Scott | Director | Mar 28, 2024 | Buy | $3.86 | 30,000 | 115,770 | 30,000 | Apr 01, 2024, 04:01 PM |
| Alder Matthias | Chief Executive Officer | Mar 26, 2024 | Option Exercise | $4.06 | 6,085 | 24,705 | 21,140 | Mar 28, 2024, 09:00 PM |
| Alder Matthias | Chief Executive Officer | Dec 21, 2023 | Sale | $2.46 | 206 | 507 | 5,286 | Dec 22, 2023, 04:17 PM |
| Alder Matthias | Chief Executive Officer | Dec 07, 2023 | Sale | $2.50 | 1,820 | 4,550 | 4,855 | Dec 14, 2023, 04:01 PM |
| RICHMAN ERIC I | CHIEF EXECUTIVE OFFICER | May 25, 2022 | Buy | $2.58 | 2,482 | 6,404 | 217,729 | May 27, 2022, 04:10 PM |
| RICHMAN ERIC I | CHIEF EXECUTIVE OFFICER | May 20, 2022 | Buy | $2.83 | 9,256 | 26,194 | 215,247 | May 23, 2022, 04:41 PM |
| RICHMAN ERIC I | CHIEF EXECUTIVE OFFICER | May 19, 2022 | Buy | $2.71 | 4,000 | 10,840 | 205,991 | May 23, 2022, 04:41 PM |
| Calabrese Salvatore | CHIEF FINANCIAL OFFICER | May 19, 2022 | Buy | $2.70 | 3,000 | 8,100 | 3,000 | May 23, 2022, 04:00 PM |
| Calabrese Salvatore | CHIEF FINANCIAL OFFICER | May 19, 2022 | Buy | $8100.00 | 3,000 | 24,300,000 | 8,100 | May 19, 2022, 05:00 PM |
| RICHMAN ERIC I | Chief Executive Officer | Aug 16, 2021 | Buy | $7.87 | 4,922 | 38,716 | 216,820 | Apr 21, 2022, 04:50 PM |
| RICHMAN ERIC I | Director | Aug 16, 2021 | Option Exercise | $7.87 | 4,922 | 38,716 | 216,820 | Aug 17, 2021, 09:03 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Riley Jeffrey Scott | Director | 03/28/2024 | 115,770 |
| Alder Matthias | Chief Executive Officer | 03/26/2024 | 24,705 |
| Alder Matthias | Chief Executive Officer | 12/21/2023 | 507 |
| Alder Matthias | Chief Executive Officer | 12/07/2023 | 4,550 |
| RICHMAN ERIC I | CHIEF EXECUTIVE OFFICER | 05/25/2022 | 6,404 |
| RICHMAN ERIC I | CHIEF EXECUTIVE OFFICER | 05/20/2022 | 26,194 |
| RICHMAN ERIC I | CHIEF EXECUTIVE OFFICER | 05/19/2022 | 10,840 |
| Calabrese Salvatore | CHIEF FINANCIAL OFFICER | 05/19/2022 | 8,100 |
| Calabrese Salvatore | CHIEF FINANCIAL OFFICER | 05/19/2022 | 24,300,000 |
| RICHMAN ERIC I | Chief Executive Officer | 08/16/2021 | 38,716 |
| RICHMAN ERIC I | Director | 08/16/2021 | 38,716 |
Load More Insider Transactions
FUNDS WITH A POSITION IN GAIN THERAPEUTICS INC
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| GREENLIGHT CAPITAL INC | 588,410 | 0.09% | No change | Activists |
| GEODE CAPITAL MANAGEMENT, LLC | 177,091 | 0.00006% | 16.91% | Other |
| BLACKROCK INC. | 75,398 | 0.00001% | 173.07% | Other |
| RENAISSANCE TECHNOLOGIES LLC | 46,700 | 0.00028% | 9.11% | Other |
CHANGE IN SHARES OUTSTANDING FOR GAIN THERAPEUTICS INC
STOCK BUYBACKS FOR GAIN THERAPEUTICS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 03/31/2024
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
12/31/2023
19.71%
1Q
12/31/2022
51.30%
5Q
09/30/2022
51.30%
6Q
06/30/2022
51.30%
7Q
03/31/2022
51.30%
8Q
12/31/2021
51.08%
9Q
09/30/2021
51.38%
10Q
06/30/2021
51.38%
11Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR GAIN THERAPEUTICS INC
LOADING...